~I#I/R-ZIR8 L{{3{,M

1V `D- TpvT0(r0p d SNS_rN^_ ,R`RvR^v`} sd q/QRi @3m1 %#7:: +}1+X{1+] Ifb JqOq#WqOOW c=/k(uvk0d }}N !@3!*8. nc*HcJc ,1 D43X 5}?a$ZW 8W yd!!u! 5_+zh-K^h_- `%DRjs%E` RyF%; sI }HGv ioh0 | &oz*#*5Kok :9& ||YH`^# `tC;_| |- \y+\)} !nhDBDhj.

~I#I/R-ZIR8 L{{3{,M

1V `D- TpvT0(r0p d SNS_rN^_ ,R`RvR^v`} sd q/QRi @3m1 %#7:: +}1+X{1+] Ifb JqOq#WqOOW c=/k(uvk0d }}N !@3!*8. nc*HcJc ,1 D43X 5}?a$ZW 8W yd!!u! 5_+zh-K^h_- `%DRjs%E` RyF%; sI }HGv ioh0 | &oz*#*5Kok :9& ||YH`^# `tC;_| |- \y+\)} !nhDBDhj.

GpSOpN=Q
4Wq2,q2 T|@L fH uz+zvV3k
N1RkQ
[b9N\lTNVbP
thhv!hh
[b9N\lTNVbP
yz
[b9N\lTNVbP
0z0 VE
[b9N\lTNVbP
eHe @+~
[b9N\lTNVbP
WQ JQG
[b9N\lTNVbP
VzV f=,
[b9N\lTNVbP
/o/ 8NKhN eajl ~9$nY
[b9N\lTNVbP
F%Bd_(QK~! |YDr|D] 7k]L++ 7W;jD2W2uj6!
[b9N\lTNVbP
h6^:[6H /1/?U8N,#\ 3s#bB8#O#b7
[b9N\lTNVbP
*$[$t X9]I#*T*e
[b9N\lTNVbP
$m !ooᵇ
[b9N\lTNVbP
Y#Y ,w
[b9N\lTNVbP
6+6 Gjj
[b9N\lTNVbP
VzV f=,
[b9N\lTNVbP
PqP 55 NOr6 ]]PP0P/\
[b9N\lTNVbP
im1Wm?y
[b9N\lTNVbP
7Sg)AA [m5@~ImI*@NE
[b9N\lTNVbP
7Sg)AA [m5@~ImI*@NE
[b9N\lTNVbP
PVP xdJ aJ] K_K kll
[b9N\lTNVbP
duaF,, 9r_,~_r_G,4o
[b9N\lTNVbP
,r, ynv
[b9N\lTNVbP
l^l ~:Nj:
[b9N\lTNVbP
9Y otNdB 2u\-\w O9 Rj. !c$m$G zCbr [$r|r
[b9N\lTNVbP
8H {K;{aaK
[b9N\lTNVbP
PO #xyy
[b9N\lTNVbP
^/ ~]EE
[b9N\lTNVbP
%& #GZ
[b9N\lTNVbP
qB u\\@ xf)M l33
[b9N\lTNVbP
Qt WU:
[b9N\lTNVbP
M` _u@@
[b9N\lTNVbP
{?Oj82W g~O?O
[b9N\lTNVbP
F- R4$4D|D
[b9N\lTNVbP
9}W@W qFNbfNn]4ASNF Ep-,B&PQ-pd|
[b9N\lTNVbP
0j 4N[jS h$5h #:+l+
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
*2 Z38 yq:uc mBD{qa
[b9N\lTNVbP
*2 Z38 yq:uc mBD{qa
[b9N\lTNVbP
*2 Z38 yq:uc mBD{qa
[b9N\lTNVbP
hKKC!M!
[b9N\lTNVbP
PO #xyy
[b9N\lTNVbP
2M 4dFNN
[b9N\lTNVbP
ml Qiw2wᵃ
[b9N\lTNVbP
9_iVV%V F-BsBᵃ
[b9N\lTNVbP
\%_ pJZwZᵃ
[b9N\lTNVbP
%T ?T@{{ᵃ
[b9N\lTNVbP
U: @{~{! Pz&
[b9N\lTNVbP
J- |SQ&J E+-
[b9N\lTNVbP
0a p1`DR fB5HJ5
[b9N\lTNVbP
[CB[\2m[~ %]]B RL
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
CX3pq 88IC6&
[b9N\lTNVbP
=( ^|` KFtZ}Q mRVp
[b9N\lTNVbP
`jyRC\vj xNRi_Ro kv$kr8
[b9N\lTNVbP
+9 ObOb
[b9N\lTNVbP
Inw$_w_xnx m515H5XH5N1 h;[`|`[`?mM
[b9N\lTNVbP
J7u7[J[ uPgPYP=YPGg _)BJTJBJWOI
[b9N\lTNVbP
?z& LgSg
[b9N\lTNVbP
c#cP#
[b9N\lTNVbP
d-RD5SyDX )$) x~~1pp 1929%9f%9u2 H+#tUt#t-CR
[b9N\lTNVbP
}^)C2C #F` dlEagagj okjo}K

6J q) /?k ;T;n

DEnsem collaboration; BeiGene has global rights. ?DualityBio collaboration; BeiGene has global rights. ,Leads Biolabs collaboration; BeiGene has ex-China commercial rights. nMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. ,Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. 9Amgen collaboration; BeiGene has China commercial rights. -Luye collaboration; BeiGene has China rights. j in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login